Tonyan ZN, Nasykhova YA, Danilova MM, Glotov AS. Genetics of macrovascular complications in type 2 diabetes. World J Diabetes 2021; 12(8): 1200-1219 [PMID: 34512887 DOI: 10.4239/wjd.v12.i8.1200]
Corresponding Author of This Article
Andrey S Glotov, DSc, PhD, Senior Scientist, Department of Genomic Medicine, D.O. Ott Research Institute of Obstetrics, Gynecology and Reproductology, Mendeleevskaya Line 3, Saint-Petersburg 199034, Russia. anglotov@mail.ru
Research Domain of This Article
Endocrinology & Metabolism
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Diabetes. Aug 15, 2021; 12(8): 1200-1219 Published online Aug 15, 2021. doi: 10.4239/wjd.v12.i8.1200
Genetics of macrovascular complications in type 2 diabetes
Ziravard N Tonyan, Yulia A Nasykhova, Maria M Danilova, Andrey S Glotov
Ziravard N Tonyan, Yulia A Nasykhova, Maria M Danilova, Andrey S Glotov, Department of Genomic Medicine, D.O. Ott Research Institute of Obstetrics, Gynecology and Reproductology, Saint-Petersburg 199034, Russia
Yulia A Nasykhova, Andrey S Glotov, Laboratory of Biobanking and Genomic Medicine of Institute of Translation Biomedicine, St. Petersburg State University, Saint-Petersburg 199034, Russia
Author contributions: All authors contributed equally to the work.
Supported byMinistry of Science and Higher Education of the Russian Federation within the Applied Science Research Program, No. AAAA-A20-120041390028-0; and Estonia-Russia Cross Border Cooperation Programme 2014-2020, No. ER24.
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Andrey S Glotov, DSc, PhD, Senior Scientist, Department of Genomic Medicine, D.O. Ott Research Institute of Obstetrics, Gynecology and Reproductology, Mendeleevskaya Line 3, Saint-Petersburg 199034, Russia. anglotov@mail.ru
Received: March 1, 2021 Peer-review started: March 1, 2021 First decision: April 20, 2021 Revised: May 4, 2021 Accepted: July 9, 2021 Article in press: July 9, 2021 Published online: August 15, 2021 Processing time: 161 Days and 6.2 Hours
Abstract
Type 2 diabetes mellitus (T2DM) is a metabolic disorder that currently affects more than 400 million worldwide and is projected to cause 552 million cases by the year 2030. Long-term vascular complications, such as coronary artery disease, myocardial infarction, stroke, are the leading causes of morbidity and mortality among diabetic patients. The recent advances in genome-wide technologies have given a powerful impetus to the study of risk markers for multifactorial diseases. To date, the role of genetic and epigenetic factors in modulating susceptibility to T2DM and its vascular complications is being successfully studied that provides the accumulation of genomic knowledge. In the future, this will provide an opportunity to reveal the pathogenetic pathways in the development of the disease and allow to predict the macrovascular complications in T2DM patients. This review is focused on the evidence of the role of genetic variants and epigenetic changes in the development of macrovascular pathology in diabetic patients.
Core Tip: Type 2 diabetes mellitus (T2DM) is often associated with life-threatening macrovascular complications which may lead to an eye injury, kidney failure, and reduction in life expectancy in patients with diabetes. This review is focused on genetic and epigenetic risk factors for macrovascular complications development in patients with T2DM.
